Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
McKesson
Johnson and Johnson
Colorcon

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Motesanib

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Motesanib?

Motesanib is an investigational drug.

There have been 13 clinical trials for Motesanib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2012.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Takeda.

Recent Clinical Trials for Motesanib
TitleSponsorPhase
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerAmgenPhase 1/Phase 2
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerSusan G. Komen Breast Cancer FoundationPhase 1/Phase 2
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerSidney Kimmel Cancer Center at Thomas Jefferson UniversityPhase 1/Phase 2

See all Motesanib clinical trials

Clinical Trial Summary for Motesanib

Top disease conditions for Motesanib
Top clinical trial sponsors for Motesanib

See all Motesanib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Mallinckrodt
Dow
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.